Skip to content

Michael H Shannon

2 papers in the library · 51 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression.

Journal of managed care & specialty pharmacy September 2026 Bridget Flavin, Gary Small, Charles Dragovich et al.

Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment. The burden of TRD impacts individuals, families, and society, with outcomes such as decreased health-related quality of life and increased health care utilization and...

Methylenedioxymethamphetamine (MDMA, “Ecstasy”)

Pediatric Emergency Care October 1, 2000 Michael H Shannon 51 citations

Ecstasy (MDMA) is an amphetamine derivative of growing popularity. The drug produces a range of toxicities when taken either in standard doses or overdose. In overdose it has major toxicity, producing several different life-threatening manifestations. Hepatotoxicity and hyponatremia are common but poorly understood consequences of MDMA overdose. The drug can produce long-term, if not permanent,...